AVTR SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that Avantor Investors Have Opportunity to Lead Class Action Lawsuit GlobeNewswire November 09, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Avantor To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in […]

(Other OTC:NJDCY), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Nidec To Contact Him Directly To Discuss Their Options If you suffered significant losses in Nidec stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at

NJDCY SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Nidec GlobeNewswire November 09, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Nidec To Contact Him Directly To Discuss Their Options If you suffered significant losses in Nidec stock or options

(NASDAQ:MNPR), WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, is presenting new data and analyses today from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver

BOSTON, Nov. 09, 2025 (GLOBE NEWSWIRE) — Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that positive interim data from its ongoing MUSIC-HFpEF Phase 1/2a clinical trial was presented at the American Heart Association (AHA) Scientific Sessions 2025 taking place November 7-10, 2025, in New

Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025 GlobeNewswire November 09, 2025 BOSTON, Nov. 09, 2025 (GLOBE NEWSWIRE) — Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that positive interim

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD – The Liver Meeting(R) 2025 GlobeNewswire November 09, 2025 WILMETTE, Ill., Nov. 09, 2025 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients

Mental Health Cooperative (MHC), one of Tennessee's leading behavioral health organizations, has partnered with safety technology company Silent Beaconto help protect MHC's frontline mental health professionals. Through this collaboration, nearly 300 MHC team members now carry discreet wearable panic buttons that, with a single press, can call 911, alert supervisors, and transmit their live GPS

(NYSE:WPP), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In WPP To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in WPP between February 27, 2025 and July 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner

WPP SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Announces that WPP Investors Have Opportunity to Lead Class Action Lawsuit GlobeNewswire November 09, 2025 Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In WPP To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in